Evidence map›Paper›PMID 32329747›Full record

ArticleJMIR research protocols2020

The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial.

Marie-Eve Carrier, Linda Kwakkenbos, Warren R Nielson, Claire Fedoruk, Karen Nielsen, Katherine Milette, Janet Pope, Tracy Frech, Shadi Gholizadeh, Laura Hummers and 26 more

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 6 countries.

Marie-Eve CarrierLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0002-5189-3350
Linda KwakkenbosBehavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, Netherlands.ORCID 0000-0002-1573-4504
Warren R NielsonSt Joseph's Health Care, London, ON, Canada.ORCID 0000-0002-2346-5594
Claire FedorukLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0003-2490-0145
Karen NielsenScleroderma Society of Ontario, Hamilton, ON, Canada.ORCID 0000-0003-1286-866X
Katherine MiletteLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0002-4755-4145
Janet PopeUniversity of Western Ontario, London, ON, Canada.ORCID 0000-0003-1479-5302
Tracy FrechUniversity of Utah, Salt Lake City, UT, United States.ORCID 0000-0002-5472-3840
Shadi GholizadehCalifornia School of Professional Psychology/Alliant, Los Angeles, CA, United States.ORCID 0000-0001-7237-0447
Laura HummersJohns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0002-4864-4011
Sindhu R JohnsonToronto Scleroderma Program, Mount Sinai Hospital & Toronto Western Hospital, Toronto, ON, Canada.ORCID 0000-0003-0591-2976
Pamela PiotrowskiPrivate practice - Nutrition, Hamilton, ON, Canada.ORCID 0000-0003-3617-5710
Lisa JewettLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0003-3554-8060
Jessica GordonHospital for Special Surgery, New York, NY, United States.ORCID 0000-0001-8068-0592
Lorinda ChungDepartments of Pediatrics, Biomedical Data Science, Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States.ORCID 0000-0003-0072-6939
Dan BilskerSimon Fraser University, Burnaby, BC, Canada.ORCID 0000-0001-6485-7263
Kimberly A TurnerLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0002-1695-0364
Julie CuminLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0003-3495-7639
Joep WellingNVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, Netherlands.ORCID 0000-0002-2179-2110
Catherine FortuneScleroderma Society of Ontario, Hamilton, ON, Canada.ORCID 0000-0002-9064-8411
Catarina LeiteUniversity of Minho, Braga, Portugal.ORCID 0000-0002-4613-0164
Karen GottesmanScleroderma Foundation, Los Angeles, CA, United States.ORCID 0000-0001-5718-2819
Maureen SauveScleroderma Society of Ontario, Hamilton, ON, Canada.ORCID 0000-0002-7919-9926
Tatiana S Rodríguez-ReynaInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0002-5799-5016
Marie HudsonLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0001-6718-2468
Maggie LarcheMcMaster University, Hamilton, ON, Canada.ORCID 0000-0002-9506-1249
Ward van BredaFaculty of Behavioural and Movement Sciences, Vrije University, Amsterdam, Netherlands.ORCID 0000-0002-7358-4444
Maria E Suarez-AlmazorUniversity of Texas MD Anderson Cancer Center, Houston, TX, United States.ORCID 0000-0001-5381-5797
Susan J BartlettDepartment of Medicine, McGill University, Montreal, QC, Canada.ORCID 0000-0001-9755-2490
Vanessa L MalcarneSan Diego State University, San Diego, CA, United States.ORCID 0000-0002-7526-9982
Maureen D MayesUniversity of Texas McGovern School of Medicine, Houston, TX, United States.ORCID 0000-0001-5070-2535
Isabelle BoutronUniversité Paris Descartes, Paris, France.ORCID 0000-0002-5263-6241
Luc MouthonUniversité Paris Descartes, Paris, France.ORCID 0000-0002-9838-246X
Fredrick WigleyJohns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0003-0762-6981
Brett D ThombsLady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0002-5644-8432
SPIN Investigators *See Acknowledgments, .
Jewish General Hospital · CAMultiple Sclerosis Society of Canada · CADélégation Paris 5 · FRJohns Hopkins University · USAlliant International University · USCanadian Nutrition Society · CAHospital for Special Surgery · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXMcGill University · CAMcMaster University · CAMount Sinai Hospital · CANederlandse Spoorwegen · NLRadboud University Nijmegen · NLSan Diego State University · USScleroderma Foundation · USStanford University · USSt Joseph's Health Care · CAThe University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic sclerosis (SSc), or scleroderma, is a rare disease that often results in significant disruptions to activities of daily living and can negatively affect physical and psychological well-being. Because there is no known cure, SSc treatment focuses on reducing symptoms and disability and improving health-related quality of life (HRQoL). Self-management programs are known to increase self-efficacy for disease management in many chronic diseases. The Scleroderma Patient-centered Intervention Network (SPIN) developed a Web-based self-management program (SPIN self-management; SPIN-SELF) to increase self-efficacy for disease management and to improve HRQoL for patients with SSc.

objectiveThe proposed study aims to assess the feasibility of conducting a full-scale randomized controlled trial (RCT) of the SPIN-SELF program by evaluating the trial implementation processes, required resources and management, scientific aspects, and participant acceptability and usage of the SPIN-SELF program.

methodsThe SPIN-SELF feasibility trial will be conducted via the SPIN Cohort. The SPIN Cohort was developed as a framework for embedded pragmatic trials using the cohort multiple RCT design. In total, 40 English-speaking SPIN Cohort participants with low disease management self-efficacy (Self-Efficacy for Managing Chronic Disease Scale score ≤7), who have indicated interest in using a Web-based self-management program, will be randomized with a 3:2 ratio into the SPIN-SELF program or usual care for 3 months. Feasibility outcomes include trial implementation processes, required resources and management, scientific aspects, and patient acceptability and usage of the SPIN-SELF program.

resultsEnrollment of the 40 participants occurred between July 5, 2019, and July 27, 2019. By November 25, 2019, data collection of trial outcomes was completed. Data analysis is underway, and results are expected to be published in 2020.

conclusionsThe SPIN-SELF program is a self-help tool that may improve disease-management self-efficacy and improve HRQoL in patients with SSc. The SPIN-SELF feasibility trial will ensure that trial methodology is robust, feasible, and consistent with trial participant expectations. The results will guide adjustments that need to be implemented before undertaking a full-scale RCT of the SPIN-SELF program. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/16799.

Indexed as

feasibility studiesscleroderma, systemicself-managementtrial protocols

Identifiers

PMID32329747
PMCPMC7210498
OpenAlexW3003085452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.